Recombinant factor VIII Fc fusion protein for first-time immune tolerance induction: final results of the verITI-8 study

Inhibitor development remains a major challenge in factor VIII (FVIII) replacement therapy. verITI-8 is the first prospective study of a recombinant FVIII Fc fusion protein (rFVIIIFc; efmoroctocog alfa) for first-time immune tolerance induction (ITI) in males with severe hemophilia A and high-titer...

Descripción completa

Detalles Bibliográficos
Autores principales: Malec, Lynn, Van Damme, An, Chan, Anthony K. C., Spasova, Mariya, Jain, Nisha, Sensinger, Charlotte, Dumont, Jennifer, Lethagen, Stefan, Carcao, Manuel, Peyvandi, Flora
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10646781/
https://www.ncbi.nlm.nih.gov/pubmed/36735911
http://dx.doi.org/10.1182/blood.2022017780

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10646781/
https://www.ncbi.nlm.nih.gov/pubmed/36735911
http://dx.doi.org/10.1182/blood.2022017780

Ejemplares similares